Saxagliptin in the Treatment of Type 2 Diabetes: A Meta-Analysis_Chinese Journal of Evidence-Based Medicine

Authors：

ZHAN Mei ,  XU Ting , WU Fengbo , WU Bin

Department of Pharmacy, West China Hospital, Sichuan University, Chengdu 610041, China;

Corresponding author：

XU Ting, Email: tingx2009@163.com

Keywords：

Saxagliptin; Type 2 diabetes; Meta-analysis; Systematic review; Randomized controlled trial

DOI：

10.7507/1672-2531.20120115

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To evaluate the efficacy and safety of saxagliptin in type 2 diabetes patients.
Methods The following databases as The Cochrane Library (Issue 2, 2011), PubMed (1978 to May 2011), EMbase (1974 to May 2011), CNKI (1978 to May 2011), VIP (1989 to May 2011) and CBM (1978 to May 2011) were searched. The quality of included randomized controlled trials (RCTs) was assessed according to the Cochrane Collaboration system review, and then meta-analysis was performed using RevMan 5.0.
Results A total of 7 RCTs were included. The results of meta-analyses showed that HbA1c was significantly reduced in the saxagliptin group than that in placebo group (MD= –0.69, 95%CI –0.78 to –0.60, P lt;0.000 01). There was no significant difference in the incident rate of adverse reaction between two groups (RR=1.02, 95%CI 0.98 to 1.06, P=0.26).
Conclusion Saxagliptin is effective and safe for type 2 diabetes. But its long-term efficacy and safety still need to be confirmed by performing more high quality, large sample RCTs with long-term follow-up.

Citation： ZHAN Mei,XU Ting,WU Fengbo,WU Bin. Saxagliptin in the Treatment of Type 2 Diabetes: A Meta-Analysis. Chinese Journal of Evidence-Based Medicine, 2012, 12(6): 708-713. doi: 10.7507/1672-2531.20120115 Copy

1.	Ryden L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary - The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). European Heart Journal, 2007, 28(11): 1401-2.
2.	Neumiller JJ, Wood L, Campbell RK. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. Pharmacotherapy, 2010, 30(5): 463-484.
3.	Higgins J, Green S. Cochrane handbook for systematic reviews of interventions version 5.0. 2 [updated September 2009]. The Cochrane Collaboration. 2009.
4.	Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2008, 10(5): 376-386.
5.	Chacra AR, Tan GH, Apanovitch A, et al. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. International Journal of Clinical Practice, 2009, 63 (9): 1395-1406.
6.	DeFronzo RA, Hissa MN, Garber AJ, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care, 2009, 32(9): 1649-1655.
7.	Hollander P, Li J, Allen E, et al. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. Journal of Clinical Endocrinology and Metabolism, 2009, 94(12): 4810-4819.
8.	Jadzinsky M, Pfutzner A, Paz-Pacheco E, et al. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: A randomized controlled trial. Diabetes, Obesity and Metabolism, 2009, 11(6): 611-622.
9.	Rosenstock J, Aguilar-Salinas C, Klein E, et al. Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes. Current Medical Research and Opinion, 2009, 25(10): 2401-2411.
10.	Scheen AJ, Charpentier G, Ostgren CJ, et al. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes/Metabolism Research and Reviews, 2010, 26(7): 540-549.
11.	Stenlöf K, Raz I, Neutel J, et al. Saxagliptin and metformin XR combination therapy provides glycemic control over 24 hours in patients with T2DM inadequately controlled with metformin. Current Medical Research and Opinion, 2010, 26 (10): 2355-2363.
12.	Green BD, Irwin N, Gault VA, et al. Development and therapeutic potential of incretin hormone analogues for type 2 diabetes. Br J Diabetes Vasc Dis, 2005, 5(3): 134-140.
13.	Ahren B. Dipeptidyl peptidase-4 inhibitors. Clinical data and clinical implicat. Diabetes Care, 2007, 30(6): 1344-1350.
14.	Colagiuri S. 餐后血糖治疗指南(IDF). 2008.
15.	杨文英. 中国2型糖尿病防治指南. 2010.
16.	Consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control (AACE/ACE consensus statement). 2009.

1. Ryden L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary - The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). European Heart Journal, 2007, 28(11): 1401-2.
2. Neumiller JJ, Wood L, Campbell RK. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. Pharmacotherapy, 2010, 30(5): 463-484.
3. Higgins J, Green S. Cochrane handbook for systematic reviews of interventions version 5.0. 2 [updated September 2009]. The Cochrane Collaboration. 2009.
4. Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2008, 10(5): 376-386.
5. Chacra AR, Tan GH, Apanovitch A, et al. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. International Journal of Clinical Practice, 2009, 63 (9): 1395-1406.
6. DeFronzo RA, Hissa MN, Garber AJ, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care, 2009, 32(9): 1649-1655.
7. Hollander P, Li J, Allen E, et al. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. Journal of Clinical Endocrinology and Metabolism, 2009, 94(12): 4810-4819.
8. Jadzinsky M, Pfutzner A, Paz-Pacheco E, et al. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: A randomized controlled trial. Diabetes, Obesity and Metabolism, 2009, 11(6): 611-622.
9. Rosenstock J, Aguilar-Salinas C, Klein E, et al. Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes. Current Medical Research and Opinion, 2009, 25(10): 2401-2411.
10. Scheen AJ, Charpentier G, Ostgren CJ, et al. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes/Metabolism Research and Reviews, 2010, 26(7): 540-549.
11. Stenlöf K, Raz I, Neutel J, et al. Saxagliptin and metformin XR combination therapy provides glycemic control over 24 hours in patients with T2DM inadequately controlled with metformin. Current Medical Research and Opinion, 2010, 26 (10): 2355-2363.
12. Green BD, Irwin N, Gault VA, et al. Development and therapeutic potential of incretin hormone analogues for type 2 diabetes. Br J Diabetes Vasc Dis, 2005, 5(3): 134-140.
13. Ahren B. Dipeptidyl peptidase-4 inhibitors. Clinical data and clinical implicat. Diabetes Care, 2007, 30(6): 1344-1350.
14. Colagiuri S. 餐后血糖治疗指南(IDF). 2008.
15. 杨文英. 中国2型糖尿病防治指南. 2010.
16. Consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control (AACE/ACE consensus statement). 2009.

Previous Article
Efficacy and Safety of Trimetazidine for Stable Angina Pectoris: A Systematic Review
Next Article
Digestive Enzyme for Dyspepsia: A Systematic Review

Chinese Journal of Evidence-Based Medicine

Saxagliptin in the Treatment of Type 2 Diabetes: A Meta-Analysis

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content